School of Medicine
Showing 451-500 of 640 Results
-
Erin Elizabeth Grady
Clinical Professor, Radiology - Rad/Nuclear Medicine
BioErin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She is actively involved nationally in the SNMMI in multiple capacities including as a Director-at-Large on the SNMMI Board of Directors, chair of the Nuclear Medicine Program Directors, a member of the General Nuclear Medicine Council board, co-chair of the Government Relations Committee and a longstanding member of the Coding and Reimbursement Committee. In addition, she is a past chair of the American Board of Nuclear Medicine and has served on the board of appeals panel, review committee and milestone development committee for Nuclear Medicine and milestone revision committee for Nuclear Radiology at the ACGME. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education in nuclear medicine, nuclear medicine’s future and is a staunch advocate for patients.
-
Laura Graham
Casual - Non-Exempt, Surgery
BioLaura is a health services researcher with a wide variety of experience in data management and analysis, including large multi-center health services and outcomes research studies, provider survey studies, and laboratory-oriented research. Her research interest include surgical outcomes research, informatics, and implementation science to translate evidence into practice. The bulk of her research experience is centered around the use and analysis of large administrative datasets collected by the Veterans Health Administration. She has been involved in a multitude of Health Services Research & Development funded and unfunded studies using these administrative data to assess surgical outcomes.
-
Philip Grant
Clinical Associate Professor, Medicine - Infectious Diseases
BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
-
Teodor Grantcharov
Professor of Surgery (General Surgery)
BioDr. Teodor Grantcharov completed his surgical training at the University of Copenhagen, and a doctoral degree in Medical Sciences at the University of Aarhus in Denmark.
Dr. Grantcharov is a Professor of Surgery at Stanford University and Associate Chief Quality Officer for Innovation and Safety at Stanford Healthcare.
Prior to joining Stanford, Dr. Grantcharov was a Professor of Surgery at the University of Toronto and Keenan Chair in Surgery at St. Michael’s Hospital in Toronto. He was the Founder of the International Centre for Surgical Safety – a multidisciplinary group of visionary scientists with expertise in design, human factors, computer- and data science, and healthcare research. He previously held Canada Research Chair in Simulation and Surgical Safety and was awarded the Queen Elizabeth II diamond jubilee medal for his contributions to clinical research and patient safety in Canada. Dr. Grantcharov was awarded the honorary fellowship of the Imperial College in London, the honorary fellowships of the Bulgarian, Danish and Brazilian surgical societies, the Spinoza Chair in Surgery from the University of Amsterdam and multiple national and international awards for his contributions to surgical education and surgical safety.
Dr. Grantcharov’s clinical interest is the area of minimally invasive surgery, while his academic focus is in the field of surgical innovation and patient safety. He has become internationally recognized as a leader in this area with his work on curriculum design, assessment of competence and impact of surgical performance on clinical outcomes. Dr. Grantcharov developed the surgical Black Box concept, which aims to transform the safety culture in medicine and introduce modern safety management systems in the high-risk operating room environment.
Dr. Grantcharov has more than 220 peer-reviewed publications and more than 200 invited presentations in Europe, South- and North America. He holds several patents and is the Founder of Surgical Safety Technologies Inc – an academic startup that commercializes the OR Black Box platform. He sits on numerous committees with Surgical Professional Societies in North America and Europe. -
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Florette K. Gray Hazard
Professor - University Medical Line, Pathology
Current Research and Scholarly InterestsMy scholarly pursuits are primarily focused on the study of death and disease in the pediatric population. It is through this work that I am able to explore fundamental concepts of neoplasia, such as histogenesis and mutagenesis, while utilizing a variety of investigational techniques.
-
Carlos Greaves
Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences
BioBorn and raised in Caracas, Venezuela. Medical school at the Central University School of Medicine, where Internship was completed.
Residency training at Stanford Medical School, Department of Psychiatry. Work in Community Mental health in Maui, Hawaii for 4 years.
Work at the Veterans Administration in Palo Alto for 3 years. Currently in Private Practice and as consulting psychiatrist at the Vaden Student Health center at Stanford -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Larry L. Green
Financial Analyst 3, Anesthesia
Current Role at StanfordFinance Manager, Department of Anesthesia
-
Sherril L. Green, DVM, PhD
Professor of Comparative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.
-
Tamar Green
Assistant Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences)
Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Maxwell Greene, MD
Clinical Assistant Professor, Neurology & Neurological Sciences
BioDr. Greene is a board-certified, fellowship-trained neurologist. He is also a Clinical Assistant Professor of Neurology at Stanford University School of Medicine.
Dr. Greene provides clinical care for adult patients with disorders of the muscles and peripheral nerves that cause weakness and numbness. He specializes in diagnosing and treating neuromuscular diseases that include amyotrophic lateral sclerosis (ALS), all types of muscular dystrophy, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and Charcot-Marie-Tooth (CMT). For CIDP and CMT, Stanford is one of the few centers of excellence in the country.
A significant part of Dr. Greene’s practice involves investigational work, where he seeks to determine the cause of a patient’s symptoms. In addition to performing the full range of diagnostic tests including interpreting biopsy procedures, he has special qualifications in electrodiagnosis and the use of electromyography and nerve conduction studies.
Treatments offered by Dr. Greene cover the complete spectrum of options, with an emphasis on immune therapies for certain conditions. For CIDP and myasthenia gravis, he administers immune globulin, steroids, plasmapheresis, and rituximab. To help manage symptoms of CMT and support areas of the body weakened by this disease, he can recommend physical therapy, occupational therapy, and foot, ankle, and knee orthotics.
For the treatment of ALS and muscular dystrophy, Dr. Greene leads a multidisciplinary team offering physical and occupational therapy, pulmonary expertise, speech and swallow expertise, nutrition counseling, social services, and specialized nursing, and works together with genetic counseling. All team members collaborate closely to ensure patients receive the care and comfort needed to meet their emotional as well as physical needs.
As part of his commitment to advancing patients’ treatment options, Dr. Greene conducts clinical research. Among his current interests are
innovative new therapies for ALS and other nerve and muscular disorders. This is an exciting time in the field of neuromuscular medicine, with real potential for treatment breakthroughs for the first time in decades. Exploring these new directions enables Dr. Greene to offer Stanford patients access to options that may not be available anywhere else.
To highlight new advances for his peers, Dr. Greene has made national and regional presentations at conferences including the American Academy of Neurology meeting. Topics include the results of a study supported in part by the National Institutes of Health: paraneoplastic antibodies as markers of Hodgkin’s disease. JAMA Neurology published Dr. Greene’s article on this research.
Dr. Greene’s achievements have earned recognition from the American Academy of Neurology and other organizations. He is also the recipient of a travel award from the American Neurological Association and a grant from the NIH National Institute of Neurological Disorders and Stroke.
A member of the American Academy of Neurology, Dr. Greene is also an active member of the Western ALS Consortium and Northeastern ALS Consortium. -
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.